Analysts review Q3 trading updates for Haleon, Reckitt, Magnum, Unilever, GSK, and Coca-Cola
Summary
Sam Ball and Jonathan McEwen analyze recent financial results for six consumer goods and pharmaceutical companies. They highlight Haleon's organic revenue growth driven by oral health and its share buyback program. Reckitt Benckiser reported a beat on net revenue and operating profit despite cost inflation, while Magnum upgraded its full-year growth outlook. Unilever and GSK both showed sales growth, with Unilever upgrading guidance and GSK citing specialty medicines. Coca-Cola beat consensus with strong volume growth and raised its full-year guidance.
Episode sections
- 0:37 – 5:47
Haleon Q3 Trading Statement
Sam Ball details Haleon's Q3 results, noting 2.6% organic revenue growth driven by oral health, despite soft cold/flu consumption. The company allocated $500m to share buybacks and expects high single-digit adjusted operating profit growth.
- 5:47 – 9:54
Reckitt Benckiser Q3 Trading Statement
Jonathan McEwen discusses Reckitt's half-year results, highlighting a beat on net revenue and operating profit despite cost inflation. The company increased its dividend and launched a new $500m share buyback program.
- 9:54 – 14:30
Magnum Ice Cream Q3 Update
Sam Ball covers Magnum's Q3 update, reporting 6.4% organic revenue growth led by volume increases. The full-year growth outlook was upgraded to 5.5%, with strong performance in Europe and emerging markets.
- 14:30 – 19:21
Unilever Q3 Trading Statement
Jonathan McEwen outlines Unilever's first-half results, showing 4.8% underlying sales growth and a 42.9% rise in free cash flow. The group upgraded its four-year sales guidance and increased its quarterly dividend.
- 19:21 – 24:10
GlaxoSmithKline Q3 Results
Sam Ball reports GSK's Q3 results, featuring a 5% sales increase driven by specialty medicines. The company reaffirmed full-year guidance and highlighted regulatory approvals for new treatments, though reported operating profit fell due to restructuring charges.
- 24:10 – 30:31
Coca-Cola Q2 Results
Jonathan McEwen presents Coca-Cola's Q2 results, with 6% organic revenue growth beating consensus. The company raised full-year guidance for both revenue and earnings per share, supported by strong volume growth.
Claims worth verifying
Haleon's Q3 revenue was up organically 2.6%, with North America up 2.5%, Europe down 0.6%, and Asia Pacific/Africa/China up 3.9%.
Unidentified speaker (UNKNOWN) ·1:14
How to verify: Haleon Q3 Trading Statement 2026, available on Haleon Investor Relations website or SEC EDGAR if filed as 6-K. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceHaleon's oral health segment grew 8.8% in Q3, while VMS was down 0.5% and respiratory health was down 2%.
Sam Ball ·1:52
How to verify: Haleon Q3 Trading Statement 2026, available on Haleon Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceHaleon allocated a further $500 million to share buybacks to be completed by full-year results in February 2027.
Sam Ball ·2:53
How to verify: Haleon Q3 Trading Statement 2026, available on Haleon Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Reckitt's half-year net revenue growth was 2.6%, coming in at £6.4 billion against £6.2 billion expected.
Jonathan McEwen ·6:47
How to verify: Reckitt Half-Year Results 2026, available on Reckitt Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Reckitt's adjusted operating profit came in at £1.5 billion against £1.4 billion expected, down 14.5% ignoring exchange rates.
Jonathan McEwen ·6:47
How to verify: Reckitt Half-Year Results 2026, available on Reckitt Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Reckitt's free cash flow fell 32.7% to £419 million reflecting lower cash generation following the essential home disposal.
Jonathan McEwen ·7:15
How to verify: Reckitt Half-Year Results 2026, available on Reckitt Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Reckitt increased its dividend by 5% to 88.6 pence a share and launched a new £500 million share buyback.
Jonathan McEwen ·7:35
How to verify: Reckitt Half-Year Results 2026, available on Reckitt Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Magnum's Q3 revenue was up 6.8% (6.4% organic), driven by volume growth of 4.1% and price growth of 2.2%.
Sam Ball ·10:14
How to verify: Magnum Q3 Trading Update 2026, available on Magnum Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Unilever's first-half revenue came in at €25.6 billion, reflecting underlying sales growth of 4.8% against 4.1% expected.
Jonathan McEwen ·14:50
How to verify: Unilever Q3 Trading Statement 2026, available on Unilever Investor Relations website. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Coca-Cola's Q2 net revenue was $13.4 billion, reflecting organic growth of 6% against consensus of 3.5%.
Jonathan McEwen ·24:31
How to verify: Coca-Cola Q2 Earnings Report 2026, available on Coca-Cola Investor Relations website or SEC EDGAR. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify Haleon's Q3 trading statement and investor presentation for details on the raw material classification change for Centrum in China.
- Check Reckitt Benckiser's latest annual report for the financial impact of the essential home business disposal on free cash flow.
- Review Magnum's supply chain restructuring costs in Unilever's segment reporting to understand the distortion in trailing P/E multiples.
- Analyze Unilever's four-year sales guidance assumptions against historical growth rates and competitor performance.
- Examine GSK's pipeline updates and regulatory approval timelines for new specialty treatments to validate sales growth drivers.
- Compare Coca-Cola's volume growth metrics against industry peers and inflation-adjusted pricing strategies.
Full transcriptexpand
- 0:03
- Unidentified speaker (UNKNOWN): You
- 0:04
- Unidentified speaker (speaker_0): are listening to The Investor Way with Sam Ball and Jonathan McEwen. If you enjoy the show, please subscribe and follow us on Twitter at TIWTweets.
- 0:20
- Jonathan McEwen: Hello and welcome to the Investor Way with myself, John McEwen, and my co-host co host Sam Ball. This week on The Investor Way, we have Halion, Wreck It, Magnum, Unilever, GSK, and Coke. Sam, do you want to kick us off with our first consumer goods company?
- 0:37
- Sam Ball: Absolutely. Get everyone warmed up for the race. So we've got a trading statement from Halion. It's a Q3 trading statement. For anyone who's not familiar, Halion Halian is the consumer goods company. that was spun out from Glaxo a few years ago, which we're covering later in the show. And it was also spun
- 0:57
- Sam Ball: out following a failed attempt by Unilever to purchase it, which we are also covering later in the show. I'll just get some of their brands up quickly. So their main brands include stuff like Centodyne, Centidyne, Aquafresh, Cortisol, Panadol,
- 1:14
- Unidentified speaker (UNKNOWN): those are
- 1:14
- Sam Ball: the main ones I recognise. There are actually lots more, so if you were to look, you would probably recognise some others. But those are the main ones for me. So Halion have come out with a Q3 trading statement, and revenue is up organically 2.6%.
- 1:31
- Sam Ball: And if we split it by geography, North America's up 2.5%, Europe is down 0.6 of a percent. Asia Pacific, is that Africa and China? I think it might be Asia Pacific, Africa and China is up 3.9%, international is up 6.9%. And if we do it by product category, oral health is up 8.8%,
- 1:52
- Sam Ball: VMS is down half a percent, pain relief is up half a percent, respiratory health is down two 2%, percent, digestive health is up 2.5%, two and a half percent, and and therapeutic skin health and other is down 0.7%.
- 2:07
- Sam Ball: So the standout really is the oral health up 8.8%. So they've said that the Q3 performance was held back by soft cold and flu consumption, leading to lower orders in North America and a raw material classification Justification change for centrum over-the-counter products in China. North America, which was up
- 2:27
- Sam Ball: 2.5%, they've said was encouraging progress and strong US execution in Centuryne
- 2:33
- Unidentified speaker (UNKNOWN): and
- 2:33
- Sam Ball: Centrum, driving consumption, growing double digits. Emerging markets, that was up 5.1%. So most of that will be included in the international, which was up 6.9%. And they said that was led by high teens growth in India, underpinned by strong centidyne growth, continued e-commerce. momentum in China, and sequential improvement
- 2:53
- Sam Ball: across the MEA. What's that Middle East and Africa? They said strong delivery of adjusted operating profit and cash generation is driving deleveraging, and they've allocated a further 500 million to share buybacks to complete by full-year Full year results in Feb 27. So for context, that's on
- 3:13
- Sam Ball: a market cap. of just under 30 billion. So it's fairly decent. It's a couple of percent. And that's on top of the dividend, which is a couple of percent as well. So you are getting a decent yield from that now. Organic revenue growth for the guidance, they're now expecting that to be around two and a half percent. And the adjusted operating profit, they're continuing to expect high
- 3:33
- Sam Ball: single-digit single digit growth at constant currency. And the CEO, Brian McNamara, actually said that. the organic revenue growth overall of 2.6% was below expectations as they navigated softness across some categories, including weaker cold cough and flu consumption, and that the turnaround plan in North America is continuing to
- 3:52
- Sam Ball: make progress. I I think I probably would give them a bit of a pass on the the cold and flu because we did have a really hot summer. So I think that cold and flu season it makes sense. It wouldn't have been as bad as previous years. I think the oral health's doing really well. I think even though these are disappointing results, you know, there's still some quite encouraging signs in there. You know, the emerging markets
- 4:12
- Sam Ball: and internationally is doing quite well. The oral health in America is doing really well. That deleveraging is continuing. And I think if you look at the valuation, it's now at a P of just over 18. It's got a dividend yield of 2.1%. But then you add in the buybacks, that's probably another two and a half percent. You are getting towards a 5% yield now.
- 4:32
- Sam Ball: And we we've said a lot of the time when we've covered it previously, as it's been deleveraging over the years, that we've liked it, but then that that yield has been a bit further off
- 4:42
- Jonathan McEwen: other
- 4:42
- Sam Ball: companies that we've compared it to. It is now starting to catch up. So I think it's a pretty good business. I wouldn't be interested in it because of opportunity. cost, but if I was looking for a consumer goods company, I think this would be right up there now. And
- 4:56
- Jonathan McEwen: I
- 4:56
- Sam Ball: think it would be one that I would seriously consider. What about you, John?
- 4:59
- Jonathan McEwen: Yeah, no, I think they're doing certainly doing a good job. The sensodyne and the toothpaste business is really valuable, and particularly in the US, huge consumer market. Emerging markets, too, that's I think promising for the group, and I guess that's where. you'd see more future growth coming from. And that's I guess the case with
- 5:19
- Jonathan McEwen: a lot of these consumer goods companies that we're going to cover. Downsides, obviously the debt, but that is being paid down. And I suppose it's really probably coming down to opportunity cost as well. We can see what you think about some of the other companies that we've got this week because they're all from that same sort of sector and see whether you have any
- 5:38
- Jonathan McEwen: thoughts about those and comparative valuations too.
- 5:42
- Sam Ball: Should we move on to one that's we've not liked as much in recent years?
- 5:47
- Jonathan McEwen: Yeah, that's right. So Wreck It Ben Kaiser, I think it's another one of those that's had a difficult five to ten years. It's similar to Unilever in that sense. They've changed chief executives a number of times, they've had a number of different sorts sort of changes in. strategy. Going back, I think it was it 2018 or might have been
- 6:07
- Jonathan McEwen: even earlier. They did take on a lot of debts. They bought um a formula business that didn't really work out. And they've been struggling since, with the exception of sort of 2020, 2021, when COVID came along, they had huge debt all sales. But aside from that, they've sort of lost direction, really.
- 6:27
- Jonathan McEwen: The latest turnaround though, and we'll come on to it in this third quarter trading statement, has been more positive. They've had half-year net revenue growth of 2.6%, which came in at 6.4 billion against 6.2 billion expected. And that was driven by better than expected performances in the
- 6:47
- Jonathan McEwen: emerging markets and the Mead Johnson nutrition business. Adjusted operating profit came in at £1.5 billion against £1.4 billion expected, which was down 14.5%, ignoring exchange rates. And the decline was due to unfavorable cost inflation and product mix, but faster than expected progress on its cost
- 7:07
- Jonathan McEwen: saving program that helped drive the beat. Free cash flow fell 32.7% to 419 million.
- 7:15
- Jonathan McEwen: reflecting lower cash generation following the essential home disposal. Net debt increased from £8.4 billion to £9.4 billion. And for 2026, the group maintained its guidance of 45% like for like net revenue growth. And the group increased its dividend by 5% to
- 7:35
- Jonathan McEwen: 88.6 pence a share and launched a new 500 million.
- 7:39
- Jonathan McEwen: share buyback. And the shares were up 7.2% in early trading on this statement. In terms of valuation, the group have a market cap of £35 billion and trade at 14.8 times forward earnings, which compares Compairs with a 10-year average of
- 7:58
- Jonathan McEwen: 17.3. And the dividend yield is 4.5%.
- 8:03
- Jonathan McEwen: I think better than expected performance and volume growth. Although I think, as I sort of alluded to before, the market reaction with the shares up over 7%, probably largely because it's been a very tough five to 10 years, with that exception of the COVID year. In terms of valuation,
- 8:23
- Jonathan McEwen: I think the turnaround, it's still early day. days, but I think you see that at 14.8 times earnings. And with some of the brands that they have, things like Vanish, Silip Bang, Calgon, Finish, Jurex, Strepsils, Gavascon, they've got a lot of very
- 8:43
- Jonathan McEwen: uh well, big stable of solid, solid brands. And I think if you were looking for something that was more of a defensive pick at the time of these sort of super AI valuations, it might be one to consider. I don't think for me it's probably at the top of the list and we'll we'll come
- 9:03
- Jonathan McEwen: through to the other ones that we've got this week in the same sector. But it could be on your list, I think.
- 9:08
- Sam Ball: I think the results are okay. But you know, with the four or five years it's had since the COVID boost kind of fell off, I just don't think I'd be that interested in it. It does have some really, really solid brands. I think overall it's got a lot better and bigger brands than Halion. I think it's interesting that the
- 9:28
- Sam Ball: emerging markets is also doing well. So
- 9:30
- Unidentified speaker (UNKNOWN): it
- 9:31
- Sam Ball: seems to be more as a sector rather than anything company specific. But yeah, uh the valuation's a little bit cheaper, but I yeah, I I think for me, I'd probably need to see a bit more from it before I was convinced, really. I think it wouldn't surprise me if, you know, in six or twelve months it's just kind of reverted back to form. That would be my concern with it.
- 9:51
- Unidentified speaker (speaker_3): Fair enough.
- 9:52
- Unidentified speaker (UNKNOWN): Okay.
- 9:52
- Jonathan McEwen: Let's move on to Magnum.
- 9:54
- Sam Ball: Yeah. So Magnum, which was spun out from Unilever a couple of years ago. So it's the ice cream company. And I'll get some of their brands up. But the main ones are Magnum, Ben and Jerry's, Cornetto, Walls, and it has it's basically well, it is the world's largest standalone ice cream company. So we
- 10:14
- Sam Ball: have covered it before multiple times. They have come out with their well, another Q3 trading update, and revenue that was up 6.8% six point eight percent, and 6.4% six point four of percent that was organic. That was driven by volume growth of four point one percent and price growth of two point two percent.
- 10:33
- Unidentified speaker (UNKNOWN): And
- 10:33
- Sam Ball: they've said that's been led by innovation and improved execution.
- 10:38
- Unidentified speaker (UNKNOWN): In
- 10:38
- Sam Ball: terms of organic sales growth across the regions, Europe and Australia and New Zealand were up eight point nine percent, America's were up three 3.9%, point nine percent, and Africa, Middle East and Asia was up seventeen 17.6%. point.
- 10:52
- Sam Ball: They've said the extended summer in Europe aided growth by an estimated 2-3% during the quarter. And full year growth outlook was upgraded from 3-5% to about 5.5%.
- 11:04
- Sam Ball: In the CEO's statement, so CEO is Peter Turkuly, Colvey, and he has said sales of our leading brands have accelerated, powered by innovation. Magnum and Heart brand grew double digit with standard performance from Magnum La Pistache, the season's number one ice cream innovation and
- 11:24
- Sam Ball: reinvigorated Solero achieved exceptional growth in Europe. Ben and Jerry's maintained momentum from Q two, again growing more than nine percent. And Cornetto grew Through sales high single digit. Yasso, our low low-calorie, calorie, high high-protein protein frozen Greek yogurt in the US.
- 11:39
- Sam Ball: continued its strong trajectory with more than 30% growth. I think that's that's basically it, really. So in terms of the valuation, it actually looks like it's now trading at a P of just under 40. I'm not entirely sure why that is. Just one sec.
- 11:57
- Sam Ball: Okay, so it's the basically the earnings have been depressed by restructuring costs.
- 12:03
- Unidentified speaker (speaker_3): Oh.
- 12:03
- Sam Ball: So a lot of it's to do with moving the supply chain and stuff out of Unilever. So there's been a lot of transitional costs. So that's basically affecting the the P ratio when you look at it. The forward P is actually more like twelve.
- 12:17
- Unidentified speaker (UNKNOWN): Oh
- 12:17
- Unidentified speaker (speaker_3): okay.
- 12:18
- Sam Ball: Yeah, that looks pretty reasonable. In terms of the yield, at the moment it's not got a dividend yield, it's not paying. dividend, but again, it's only been kind of recently spun out on those numbers. If it wants to pay one, it absolutely can. In terms of the share price, it's done really well since it's been spun out.
- 12:38
- Sam Ball: It's up about 50% since it was spun out from Unilever. So yeah, I like it. I think there's a lot to like. I know you've expressed concerns
- 12:46
- Unidentified speaker (UNKNOWN): about
- 12:46
- Sam Ball: the the super users dropping off because of the GLP ones. But at the minute that isn't happening. I don't really know enough about kind
- 12:54
- Unidentified speaker (speaker_3): of
- 12:55
- Sam Ball: how the sales are made up in terms of w what is the super u users.
- 12:59
- Unidentified speaker (UNKNOWN): I do
- 12:59
- Sam Ball: agree those long-term concerns, but on these results I think they're pretty good. We covered it last time, but they're taking control of the Magnum comp what is basically Magnum in India, so
- 13:12
- Unidentified speaker (UNKNOWN): which
- 13:12
- Sam Ball: is has probably contributed towards those uh emerging markets figures. But yeah, I I th I think it's doing really, really well. I can see why you'd have those long term concerns with the GLP ones, but in terms of the operational performance, given that it is an ice cream company, I guess yeah, they've got its early days, but they've got that high protein yogurt in
- 13:32
- Sam Ball: America. Yeah, It seems to be growing very well. I think they're doing everything they can other than stopping selling ice cream. So yeah, I I think there's a lot to like. What about you, John?
- 13:42
- Jonathan McEwen: Yeah, no, I mean I think it operationally fantastic. And at the valuation on that forward PE of what, twelve, it looks really cheap. If you'd asked me ten years ago, I'd have been buying it all day Very long. I think now, as you say, my concern would be the long term threat from
- 14:01
- Jonathan McEwen: GLP ones. Who knows when that's really going to start hitting the numbers here and hitting both top and bottom line? Really difficult to say, but I think that would just undermine it for me and why I wouldn't actually buy shares. I did have shares in Magnum when they were spun out from Unilever. I
- 14:21
- Jonathan McEwen: have sold them now, but I think it'll be an interesting one to watch, but probably from the sideline. sidelines for me.
- 14:27
- Sam Ball: Should we move on to the company it was spun out from then?
- 14:30
- Jonathan McEwen: Yes, so Unilever, it's also one that I think it was one of my first stocks. I have now sold it, but they had their Q3 trading statement out with first half revenue coming in at 25.6 billion euros, reflecting underlying sales growth of 4.8%. Against 4.1%
- 14:50
- Jonathan McEwen: extended. expected. All business divisions contributed positively, with the growth driven by a 4.2% uplift in volumes and higher prices accounting for the remainder. Underlying operating profit rose at a slower pace of 0.9% to 5.2 billion euros, as currency headwinds and commodity inflation largely offset
- 15:10
- Jonathan McEwen: top line and efficiency improvements. Free cash flow rose by 42%. 42.9% to 1.5 billion euros, driven by strong cash conversion, and net debt decreased by around 400 million euros to 26 billion euros. The group completed 1.5 billion euros in share buybacks during the period and increased the quarterly dividend by 3%
- 15:30
- Jonathan McEwen: to 46 cents a share. Four-year guidance was upgraded with underlying sales growth expected to be between 4 and 6%. respectively. Previously it was at the lower end of this range, including volume growth of around 3%, and the shares were up nearly 5% in early trading. In terms of valuation,
- 15:50
- Jonathan McEwen: Unilever has a market cap of £106 billion and trades at 16.3 times forward earnings, compared with a 10-year average of 17.7, and it has a prospective dividend yield of 3.5. 3.7%.
- 16:04
- Jonathan McEwen: I thought this was a really decent set of results from Unilever, with growth driven both by volumes and prices, and particularly if it can continue that momentum. I think there is certainly more risk with Unilever than there used to be, when it was that huge conglomerate
- 16:24
- Jonathan McEwen: and had all of the different divisions and Magnum or the ice cream business being one of them, we have seen with those sold off over the last few years and this increased focus under Fernando Fernandez, the current chief executive, on making Unilever essential, essentially
- 16:44
- Jonathan McEwen: personal care and beauty. I think if he can carry it off, it you know there are. higher margins there and there is potential for much greater growth, but I think it's risky. I didn't like the strategy and the move away from Unilever being that big conglomerate with all
- 17:04
- Jonathan McEwen: of that broad spread of brands. I think also ending up with, or what Unilever you leave a shareholders will have, which is McCormick shares in exchange for. the food division. Didn't like that either. It's difficult to know how things are going to go. It could be that this strategy, albeit higher
- 17:24
- Jonathan McEwen: risk, does pay off with the personal care business, but it's a really, really competitive sector, and you're going up against the likes of L'Oreal et al. So, yeah, it wouldn't be one for me. anymore. I think Unilever has changed. And for me, again, we've seen so many
- 17:44
- Jonathan McEwen: chief executives over the last 10 years all trying to execute different sort of turnaround strategies. And none of them hitherto have really worked. So again, I think it'll be interesting to watch from the sidelines, but I I wouldn't be buying shares now. Sam, what are your thoughts?
- 18:02
- Unidentified speaker (UNKNOWN): Yeah,
- 18:02
- Sam Ball: I thought the results were pretty decent. I think interesting that emerging markets, again, double digits in a lot of regions. So again, it's again not company specific. I think I just had a quick look at McCormick actually, because we've not covered it, I think, for four or five years, and it was really, really expensive. It's actually
- 18:22
- Sam Ball: down forty percent in five years. So I think because they are being partly paid in McCormick shares it's probably not as bad as I thought it was 'cause they're not at least getting shares that are trading at like thirty five times earnings in exchange for their Unilever ones at whatever it is, like seventeen. So it's probably come down to a similar valuation, but yeah, yeah, as
- 18:42
- Sam Ball: we've talked about before, I don't love the strategy. I think those brands were stronger together. It kind of is what it is, but I think for me it would make Unilever a lot less attractive. Certainly the standalone Unilever that's left. So yeah, it just it just wouldn't interest me because of the direction it's going in. Sure. Even if it did, I think the numbers are pretty good,
- 19:02
- Sam Ball: but having again when we've seen what we've seen from it over the last kind of five years where it might have a couple of good quarters and then rev again revert back to form, would I pay nearly twenty 20 times earnings for it? I probably wouldn't because I'd
- 19:15
- Unidentified speaker (UNKNOWN): have
- 19:15
- Sam Ball: concerns that it's going to drop down back to kind of 1716 anyway.
- 19:19
- Jonathan McEwen: Yeah, yeah. How are Glaxo doing?
- 19:21
- Sam Ball: So, Glaxo SmithKline. So they are the pharmaceutical company. They have come out with Q3 results and they've reported a 5% increase in sales, driven by strong growth in specialty medicines. As the pharmaceutical giant reaffirmed, it's full. year guidance. So turnover rose four percent
- 19:41
- Sam Ball: at actual exchange rates and five percent at constant currencies. Core operating profit increased five percent, and core earnings per share was up one percent, reflecting higher sales in a favorable product mix, partly offset by increased R and D spending and higher finance costs. Reported operating profit, however, fell
- 20:01
- Sam Ball: sixteen 16% percent to $2.13 billion, partly reflecting $328 million of restructuring charges relating to its accelerate growth program. Specialty medicines rose 15% to $3.9 billion, with HIV medicines up 10% to $2.1 billion. Respiratory, immunology, and inflammation
- 20:21
- Sam Ball: treatments ahead around 21% to $1.1 billion, and oncology revenue increased. increasing 23% to 600 million. Vaccine revenue declined 2% as Changrix sales fell 5%, while meningitis vaccines grew 12%. General medicine sales were flat at 2.4
- 20:41
- Sam Ball: billion, with trilogy revenue rising 8%. They've reaffirmed full-year full year guidance for sales growth of 3% to 5% and core operating profit of 7-9% 7 to 9% growth.
- 20:51
- Sam Ball: which are both towards the upper half of their ranges, while core earnings per share was expected towards a lower half of 7 to 9%. And the CEO has highlighted recent regulatory approvals for chronic hepatitis B treatment, hip sargo, and gemparilli for rectal cancer, and said the company was on track to initiate twenty-two 22 phase
- 21:11
- Sam Ball: three trials this year. In terms of valuation, the business trades at a P of 11 and has a dividend yield of 3.5%.
- 21:19
- Sam Ball: I think these results for the valuation are actually pretty decent. I think the headline figures aren't amazing, but then when you dive in, there's quite a few segments where it's quite encouraging. Where I struggle is the pipeline. You know, the CEO paints quite an encouraging picture, but the P of 11 eleven suggests the market may. maybe doesn't
- 21:39
- Sam Ball: agree.
- 21:40
- Unidentified speaker (UNKNOWN): And
- 21:40
- Sam Ball: I would just have concerns that I don't have any way of kind of knowing what's going to happen with that. I don't really have any expertise in terms of trial, medical trials and stuff like that.
- 21:50
- Unidentified speaker (UNKNOWN): So
- 21:51
- Sam Ball: yeah, it it does look good at a P of eleven, but with that caveat that I I don't understand how to properly analyze the pipeline and whether the market's actually just, you know, actually valuing it fairly accurately. But I thought it was a good set of results and quite a lot in there to be optimistic about. What do you think, John?
- 22:09
- Jonathan McEwen: Yeah, no, I I tend to agree with you. I think the difficulty with pharmaceutical companies always is being able to analyse the pipeline, and that is absolutely critical in the valuation and the future revenue. In terms of Glaxo, I think it'd be fair to say the last 10, 15 years. it has been fairly
- 22:28
- Jonathan McEwen: lackluster. Obviously they've spun out their consumer goods division, which is now Halian. But when you compare them over the last 10, 15 years with AstraZeneca, which used to be I don't know if it was half the size of Glaxo, and now it's sort of double, that does show So if you have the right drugs and certainly
- 22:48
- Jonathan McEwen: when it came to AstraZeneca, they had an incredible oncology pipeline and it's just grown and grown and grown, and how much Glaxo's fallen behind on that? I think Glaxo did have a good immunisations and sort of vaccinations division, but that's now actually been the weaker performer. The oncology sounds like
- 23:08
- Jonathan McEwen: it's been doing quite well, but in terms of having some sort of blockbuster drug. drugs, it doesn't sound really like they've they've managed to achieve any that have moved the dial significantly. The other thing is when you do look at the pharmaceutical sector, and we've covered Eli
- 23:27
- Jonathan McEwen: Lilly on the show before, the sort of drugs, particularly with their exposure to sort of obesity and diabetes, it's driven growth massively.
- 23:39
- Jonathan McEwen: And yes, it does come at a higher valuation, but the quality of their portfolio is on another level. So I guess if you had a deeper knowledge of the pipeline and you were looking for a value play, I can see the argument to be made for Glaxo. But for me, I think it would go into
- 23:59
- Jonathan McEwen: the too hard pile and there'd be an element of opportunity. cost there. So I wouldn't go for it on that basis.
- 24:06
- Sam Ball: Should we move on then to a business that's a lot easier to
- 24:09
- Unidentified speaker (UNKNOWN): understand? Yeah,
- 24:10
- Jonathan McEwen: I knew you were going to say that, Sam. Yeah, absolutely. And probably isn't as good for your health. So Coca-Cola, Daddy Coke over in the US, they had their second quarter results out with second quarter net revenue coming in at $13.4 billion, reflecting organically. organic growth of 6% against consensus of 3.5%.
- 24:31
- Jonathan McEwen: The top line beat was driven by better than expected volume growth with positive contributions from all regions, which more than offset weaker than expected price growth. Underlying operating profit grew 6%, ignoring exchange rate impacts to $4.8 billion. Free cash flow over the first half.
- 24:51
- Jonathan McEwen: was $6.9 billion, and net debt fell by $1.6 billion to $30 billion since the beginning of the year. Full year guidance was raised with net revenue expected to grow by around 5% on an organic basis, previously guided at between 4 and 5%, and underlying
- 25:11
- Jonathan McEwen: earnings per share is now expected to rise by 7 to 8%.
- 25:15
- Jonathan McEwen: against the previous 6-7% guided. And the shares were up 4.3% in pre-market trading. In terms of valuation, Daddy Coke has a whopping $412 billion market cap and trades at 24.8 times forward earnings against its 10-year
- 25:35
- Jonathan McEwen: average of 22.8%, and it has a prospective dividend. yield of 2.7%.
- 25:41
- Jonathan McEwen: I thought these results were pretty incredible given that you've got a company the size of Coke, and you think with the saturation of Coca-Cola that had organic growth of 6%,
- 25:54
- Jonathan McEwen: and that on volume growth as well. I suppose when it comes to Coke, it's not just Coca Cola, they've got a whole put. portfolio of brands with Fanta included in that. In terms of its model of operation, I know we've covered this a lot of times before, and it's
- 26:13
- Jonathan McEwen: essentially owns the brand, owns the formulas, and then it's down to bottling partners, so companies like Coca-Cola HBC that it will then license out to. So it's it effectively makes Coke a branding and profit machine and capital light on that
- 26:33
- Jonathan McEwen: basis. It is probably the strong, well, one of the strongest, if not the strongest, brand in the world. It's never going to be cheap. And if you actually look at it, it's it just continues to perform. You think, how can it continue to do what it's doing? But it seems to defy
- 26:52
- Jonathan McEwen: gravity in that sense. Other things that are positive about it, I think if you were a defensive investor, if you were worried about really toppy AI valuations or businesses being threatened by AI, well, yes, Coca-Cola is not cheap, but it's probably about as defensive as you can get. So if you
- 27:12
- Jonathan McEwen: took a long-term long term view with it, I personally would struggle with 24.8 times forward earnings, but equally I I can see why people might um sit see it with that brand and just taking a you know a long term view on it. I don't think I have a huge amount more to add. I think one thing that if you were considering
- 27:32
- Jonathan McEwen: investing in Coca-Cola would be whether you did choose one of its bottling partners. So Coca-Cola HBC may be being potentially more attractive if you were looking at more rapid growth, particularly because it has that sort of more emerging markets exposure. But it
- 27:52
- Jonathan McEwen: equally, if if you wanted ultimate defensive, then there's not m much better than Coca-Cola. Sam, your thoughts?
- 28:01
- Sam Ball: Very similar. Superb set of results for the size of the company, as we talked about last time we covered it, and it had done another superb set of results. It continues to defy expectations, but I think for me, I would have concerns that that PE, even with the forward PE kind of dropping down to like 25 or
- 28:20
- Sam Ball: 24, I would be concerned about how sustainable that growth is, because I I j still make maintain that I think Coca-Cola is pretty saturated everywhere you go.
- 28:32
- Unidentified speaker (speaker_3): I
- 28:32
- Sam Ball: don't understand how they're putting these figures up actually. But yeah, I I just I would have concerns and I think there's no doubt about the quality. It's probably one of the highest quality businesses in the world. But yeah, like you said, I'd rather just go for Coca-Cola or HBC, because I think you can easily identify where that future growth comes from. and it's actually, I think, at a
- 28:51
- Sam Ball: lower P anyway. So yeah, really, really great business, can't knock it, but I just wouldn't be willing to pay that valuation for such a mature business.
- 29:00
- Jonathan McEwen: Okay. In terms of the companies this week, Halian, Recits, Magnum, Unilever, Glaxo, and Coke, what would be a top pick and what would be last?
- 29:10
- Sam Ball: It's quite tough, actually. I think I think Glaxo is quite. an easy last because it's in the too hard pile. If I was excluding that, it would be Racket. Top pick. I I do like Magnum at that price. I think I would probably go with Halion though. What about you?
- 29:29
- Jonathan McEwen: Yeah, no, it it's similar. I think Magnum on the valuation, but what what puts me off, as I said before, is the GLP ones. So that for me would mean it it's crossed off. Halion, I think, in terms of the brand, the direction, momentum with it, I would go for that as the top pick. And
- 29:49
- Jonathan McEwen: last, I go for Glaxo, because I think as a pharmaceutical, it it it does go into the too hard pile.
- 29:55
- Unidentified speaker (UNKNOWN): I
- 29:56
- Sam Ball: think that's everything in that case.
- 29:57
- Jonathan McEwen: Thank you very much for listening, and we will see you again next week.
- 30:00
- Sam Ball: See you next week.
- 30:05
- Unidentified speaker (speaker_0): Thank you for listening to the Investor Way. To get in touch, please follow us on Twitter at TiWTweets. This podcast is for entertainment purposes only and does not constitute financial advice. Neither Sam nor Jonathan are Our financial advisors. For investment advice, please consult
- 30:25
- Unidentified speaker (speaker_0): professional advisors.